COVID-19 pandemic; transmembrane protease serine 2 (TMPRSS2) inhibitors as potential drugs.
Ongoing search for treatment to ease COVID-19 pandemic concentrate on development of a vaccine or medication to prevent and treat this disease. One of the possibilities is developing new antiviral drugs that are aiming at both a virus replication or the host factor(s) that are critical to virus’s re...
Main Author: | Jerzy Jankun |
---|---|
Format: | Article |
Language: | English |
Published: |
The University of Toledo
2020-04-01
|
Series: | Translation |
Subjects: | |
Online Access: | https://openjournals.utoledo.edu/index.php/translation/article/view/361 |
Similar Items
-
Association of the Transmembrane Serine Protease-2 (TMPRSS2) Polymorphisms with COVID-19
by: Rosalinda Posadas-Sánchez, et al.
Published: (2022-09-01) -
RAndomized Clinical Trial Of NAfamostat Mesylate, A Potent Transmembrane Protease Serine 2 (TMPRSS2) Inhibitor, in Patients with COVID-19 Pneumonia
by: Teresa Maria Seccia, et al.
Published: (2023-10-01) -
RECURRENT OF TMPRSS2 GENETIC POLYMORPHISM AND ITS ROLE IN IRAQI PATIENTS WITH PROSTATE CANCER
by: Ammar K. A., et al.
Published: (2022-04-01) -
Virtual Screening of Natural Products against Type II Transmembrane Serine Protease (TMPRSS2), the Priming Agent of Coronavirus 2 (SARS-CoV-2)
by: Noor Rahman, et al.
Published: (2020-05-01) -
Type II Transmembrane Serine Proteases as Modulators in Adipose Tissue Phenotype and Function
by: Qingyu Wu, et al.
Published: (2023-06-01)